EVs also contribute to cancer drug resistance: for example, EVs from CD133+ cancer stem cells in CRC promote the tumorigenic capabilities of Cancer stem cells (CSCs) and inhibit the antitumor activity of drugs like oxaliplatin [162]. The gene discussed is PROM1; the disease is cancer.